Without the help of genomics specialists, it is hard for health plans to manage genomic benefits efficiently and effectively. Now is the time for health plans to evaluate their genomic benefits management programs to find the right expert guidance and utilization management support.
Many genetic findings are ambiguous, leaving doctors uncertain about whether a particular variant is truly dangerous.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Unlike inherited genetic predispositions, accumulated genetic changes are the result of environmental influences, such as smoking, chemicals or ultra-violet radiation. A growing body of research links somatic changes to an increased likelihood of blood cancers and cardiovascular disease, both heart disease and stroke.
Molecular diagnostics companies have laid the foundation for nothing short of a revolution in cancer care — it’s time for the medtech sector to develop tools to make genomic testing accessible to the masses.
With more individuals exploring their family tree, it’s reasonable to believe many of them are als intent to get a handle on their potential for various hereditary diseases. With that in mind, Ochsner Health has launched a digital population health pilot program.
To help cut down cancer disparities and deaths, OSF HealthCare recently announced that it will be expanding its genetic cancer risk assessment software into its Epic electronic health record for primary care practices.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The risks associated with ignoring genetic factors far exceed the complications of including them and going forward there will be more clinical trials having a genetic or precision medicine component to develop targeted therapies.
A recent study notes that widespread access to personal genetic information – without the knowledge of how to interpret results – can lead to problems ranging from misinterpretation to emotional distress.
The Food and Drug Administration has granted 23andMe the first-ever authorization for direct-to-consumer genetic testing for cancer risk without a prescription.
Distrust in genetic sequencing and medical testing abound, but the fact is that genomic medicine is a breakthrough tool for diagnosis and treatment.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
A family member's liquid biopsy test, gene testing and a journey into coverage decisions and clinical guidelines reveal how difficult the reimbursement path is for these emerging technologies.